OptimizeRx Launches Patent-Pending NLAB AI Audience Builder Ahead of August Rollout
OPRX•OptimizeRx has launched its patent-pending Natural Language Audience Builder (NLAB), an AI-powered tool enabling pharma and agency marketers to build custom, verified HCP audiences via natural-language prompts within DSPs and media planning platforms. NLAB, combining real-world evidence with proprietary EHR network data, will be available for integration from August 2026.
1. Introduction of NLAB Tool
OptimizeRx has launched the patent-pending Natural Language Audience Builder (NLAB), an AI-driven tool designed to embed within demand-side platforms and agency media planning systems. NLAB enables life sciences and agency marketers to construct and manage custom, verified HCP audiences using natural-language prompts, integrating real-world evidence with proprietary EHR network data.
2. Key Features and Functionality
NLAB allows marketers to build and refine custom NPI lists without coding or analyst support, view and rank HCP profile details such as specialty, patient volume and prescribing behavior, and assess NPI-level reach across programmatic, social, EHR and field force channels. The tool identifies which providers are most likely to engage and act on EHR advertising.
3. Market Position and Growth Potential
By extending programmatic access to its authenticated EHR inventory, OptimizeRx positions itself as an infrastructure partner for life sciences manufacturers, agencies and DSPs. Embedding audience intelligence directly into platform workflows is expected to strengthen client value propositions and create new recurring revenue streams for OptimizeRx.
4. Availability and Integration Timeline
NLAB will be available for integration from August 2026 and can be bundled with the company’s point-of-care inventory solutions. Interest from potential partners can be directed to OptimizeRx’s Strategic Partnerships team for integration details and bundle options.
